Financhill
Back

Black Diamond Therapeutics Quote, Financials, Valuation and Earnings

Sell
45

BDTX
Black Diamond Therapeutics

Last Price:
5.43
Seasonality Move:
25.38%

7 Day Trial

ALL ACCESS PASS

$ 7

Black Diamond Therapeutics Price Quote

$5.43
-0.01 (-5.4%)
(Updated: May 16, 2024 at 5:57 AM ET)

Black Diamond Therapeutics Key Stats

Sell
45
Black Diamond Therapeutics (BDTX) is a Sell

Day range:
$5.40 - $5.86
52-week range:
$1.57 - $7.66
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.93%

Volume:
2.5M
Avg. volume:
740.6K
1-year change:
181.87%
Market cap:
$306.1M
Revenue:
$0
EPS:
$-1.66

How Much Does Black Diamond Therapeutics Make?

Data Unavailable

Is Black Diamond Therapeutics Growing As A Company?

Data Unavailable

Black Diamond Therapeutics Stock Price Performance

What Is Black Diamond Therapeutics 52-Week High & Low?

Black Diamond Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Black Diamond Therapeutics?

Is Black Diamond Therapeutics Cash Flow Positive?

  • What Is BDTX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$67.9M
  • What Is Black Diamond Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $76M
  • What Is Black Diamond Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$22.2M

Black Diamond Therapeutics Return On Invested Capital

Data Unavailable

Black Diamond Therapeutics Earnings Date & Stock Price

Black Diamond Therapeutics Competitors

Black Diamond Therapeutics Dividend Yield

Data Unavailable

Black Diamond Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 18.22%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 12.80
Upside from Last Price: 135.29%

Major Shareholders

  • How many BDTX shares are owned by institutional investors?
    60.5M BDTX shares are owned by institutional investors
  • How many BDTX shares are owned by insiders?
    1.2M BDTX shares are owned by insiders